Home | Welcome to Contract Pharma   
Last Updated Thursday, October 30 2014
Print

Financial Report: Biogen Idec



Published January 31, 2012
Biogen Idec

4Q Revenues: $1.3 billion (+9%)

4Q Earnings: $300.2 million (+10%)

FY Revenues: $5.0 billion (+7%)

FY Earnings: $1.3 billion (+41%)

Comments: Tysabri revenues increased 11% in the quarter to $269 million. Global in-market sales were $380 million, up 14%. Avonex revenues were up 8% in the quarter to $703 million. Rituxan revenues from the company’s joint business arrangement were flat at $258 million in the quarter. For the year Tysabri revenues were up 20% to $1.1 billion with global in-market sales of $1.5 billion, up 23%. Avonex revenues were up 7% for the year to $2.7 billion. Rituxan sales were $1.0 billion for the year, down 7% due certain royalties from individual countries expiring and a charge of approximately $50 million related to Genentech’s arbitration with Hoechst GmbH.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On